Gilead Sciences, Inc.(GILD)Earnings, Financials & Key RatiosGilead Sciences, Inc. (GILD) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a healthy current ratio of 1.97 as of 2026Q1, the persistent reliance on non-cash acquisition-related charges complicates the assessment of underlying earnings quality.
Gilead Sciences, Inc. (GILD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Gilead Sciences, Inc. (GILD) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $2.03vs $1.91+6.3% | $7.0Bvs $6.9B+0.7% |
| Q1 2026 | Feb 10, 2026 | $1.86vs $1.81+2.8% | $7.9Bvs $7.7B+3.1% |
| Q4 2025 | Oct 30, 2025 | $2.47vs $2.13+16.0% | $7.8Bvs $7.4B+4.3% |
| Q3 2025 | Aug 7, 2025 | $2.01vs $1.96+2.6% | $7.1Bvs $7.0B+1.4% |
Recent stock market news and headlines for Gilead Sciences, Inc. (GILD)
On July 07, 2026, Gilead Sciences Inc (GILD) shares rose 5.2% today, with the current price at $136.36. Over the past year, the stock has seen a 25.2% increase.
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.
HSBC upgraded Gilead Sciences Inc. (NASDAQ:GILD) on Monday, citing that the consensus is ‘too pessimistic' in its assumptions of continued decline once dolutegravir faces generics.
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you... Here Are Monday's Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
Key metrics vs top competitors for Gilead Sciences, Inc. (GILD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $136.36 | $169.3B | 20.11 | 2.39% | 28.9% | 40.66% | 2.34% | |
| $254.65 | $449.91B | 107.45 | 8.57% | 5.79% | 67.46% | — | |
| $57.97 | $118.36B | 16.80 | -0.22% | 15.01% | 38.96% | — | |
| $368.10 | $198.66B | 25.87 | 9.92% | 20.95% | 89.41% | — | |
| $205.70 | $30.37B | 23.30 | 1.39% | 13.92% | 7.55% | — | |
| $676.23 | $70.26B | 16.30 | 0.99% | 29.65% | 14.32% | — |
Gilead Sciences, Inc. (GILD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Gilead Sciences, Inc. (GILD) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
May 4, 2026·SEC
Apr 28, 2026·SEC
Get notified when GILD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Gilead Sciences, Inc. (GILD) stock FAQ — growth, dividends, profitability & financials explained
Gilead Sciences, Inc. (GILD) reported $29.73B in revenue for fiscal year 2025. This represents a 88924% increase from $33.4M in 1996.
Gilead Sciences, Inc. (GILD) grew revenue by 2.4% over the past year. Growth has been modest.
Yes, Gilead Sciences, Inc. (GILD) is profitable, generating $9.22B in net income for fiscal year 2025 (28.9% net margin).
Yes, Gilead Sciences, Inc. (GILD) pays a dividend with a yield of 2.34%. This makes it attractive for income-focused investors.
Gilead Sciences, Inc. (GILD) has a return on equity (ROE) of 40.7%. This is excellent, indicating efficient use of shareholder capital.
Gilead Sciences, Inc. (GILD) generated $10.23B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
